Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alcaftadine in Allergic Conjunctivitis
NCT01808768Phase 4Unknown
- Start
- Apr 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alcaftadine in allergic conjunctivitis (AC) and Rhinoconjunctivitis (RC). Primary endpoint: Quality of Life- Eye Allergy Patient Impact Questionnaire at 4 months. Status: unknown.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT01808768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808768.